01801 INNOVENT BIO
- 39.600
- +0.100+0.25%
INNOVENT BIO News
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
CEO Yu Dechao reduced his holdings of Cinda Biotech (01801) by about 906,300 shares at a price of about HK$40.37 per share
On May 3, CEO Yu Dechao reduced his holdings of Cinda Biotech (01801) by 9062,500, at a price of HK$40.3726 per share, for a total amount of approximately HK$3.587,700.
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
UBS: Maintaining Cinda Biotech's (01801) “Buy” Rating Target Price Reduced to HK$57.4
Cinda Biotech (01801) maintains its domestic sales target of RMB 20 billion in 2027.
De-Chao Michael Yu sold 906,300 common shares of Cinda Biotech (01801.HK) worth approximately HK$36.5877 million
On May 9, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 9, De-Chao Michael Yu sold $9063 million shares of $Cinda Biotech (01801.HK) at an average price of HK$40.3726 per share on May 3, worth approximately HK$36.587,700. After the sale, De-Chao Michael Yu's latest shareholding was 129 million shares, and the good position ratio dropped from 8.00% to 7.94%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, the majority shareholder (holding
A quick look at the Hong Kong market | The three major indices rose sharply, and the Tech Index rose nearly 2%; TechNet stocks and Apple concept stocks improved, Meituan rose nearly 4%, and BYD Electronics rose more than 9%
Domestic housing stocks were popular. Shimao Group rose more than 33%, and Sunac China rose 10%; beer stocks rose by many stocks, China Resources Beer rose nearly 5%, and Budweiser Asia Pacific rose 4%.
Head-to-head efficacy with high-dose glycosylating peptides. The first phase III clinical study on diabetes mast peptides reached the end of the study
San Francisco, China, May 9, 2024/PRNewswire/ -- Cinda Biopharmaceuticals Group (HKSE: 01801), a biopharmaceutical company dedicated to the development, production and sale of innovative drugs for major diseases such as tumors, autoimmunity, metabolism, cardiovascular, and ophthalmology, today announced the phase III clinical study (R&D code: IBI362) of the glucagon-like peptide-1 receptor (GLP-1R) /glucagon receptor (GCGR) dual agonist (R&D code:) in subjects with type 2 diabetes in China (DREAMS-2) Reached the ultimate
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
With the magic pill for weight loss, Novo Nordisk (NVO.US), whose profits have increased dramatically, may “lose McCity” at home
In 2024, the concept of diet pills is still very popular. On May 2, Novo Nordisk (NVO.US) revealed its 2024 Q1 earnings report. Its current profit exceeded expectations, thanks to a surge in market demand for diet pills.
Bank Rating | CCB International: Raising Cinda Biotech's Target Price to HK$54.7 to Maintain “Outperform the Market” Rating
GLONGHUI, May 6 | CCB International released a report stating that Cinda Biotech's total product revenue for the first quarter increased by more than 60% year-on-year to more than 1.7 billion yuan (10% year-on-year increase in the same period last year), accounting for 24.2% of the bank's total revenue forecast for this year. The bank raised Cinda Biotech's total revenue forecast for 2024 to 2026 by 6%, 7%, and 6%, respectively, to 7.8 billion, 10.3 billion and 14.8 billion yuan, raising the bank's forecast for the company's total product revenue growth this year from 23% to 30%, and next year's forecast from 32% to 34%. Given the cost of sales required to drive higher product revenue, the bank will
Cinda Biotech (01801.HK) grants 3,371 share options and 9551 restricted shares
Gelonghui, May 3, 丨 Cinda Biotech (01801.HK) announced that on May 3, 2024, the company granted 3,371 share purchase rights to independent non-executive director Chen Shuyun in accordance with the terms of the initial public offering after-sales employee share ownership plan, subject to Chen's acceptance. The board of directors announced that on May 3, 2024, the company granted 9551 restricted shares to Chen Shuyun in accordance with the 2020 Restricted Shares Plan, subject to Chen's acceptance and approval by independent shareholders at the Annual General Meeting of Shareholders.
Cinda Biotech (01801): Zhang Qian was appointed as Executive Director and Strategy Committee Member
Cinda Biotech (01801) announced that since May 3, 2024, Mr. Chen Shuyun has been appointed as an independent non-...
CCB International: Maintaining Cinda Biotech's (01801) “Outperform the Market” rating and raising the target price to HK$54.7
According to CCB International, Cinda Biotech (01801) is one of the bank's preferred stocks in the Chinese pharmaceutical industry.
Cinda Biotech (1801.HK): Strong revenue growth in the first quarter, various products will be unveiled at the ASCO conference
Core view The company's revenue for the first quarter of 2024 exceeded 1.7 billion yuan, a strong year-on-year increase of more than 60%. At the same time, sales continued to grow month-on-month under the influence of the 24Q1 Spring Festival. Sales exceeded 1.6 billion yuan in the fourth quarter of '23, and performance performance
Changes in Hong Kong stocks | Cinda Biotech (01801) is now up more than 9%, and total product revenue in the first quarter has increased by more than 60%. The company will release multiple clinical data at ASCO
Cinda Biotech (01801) is now up more than 9%. As of press release, it is up 9.02% to HK$41.7, with a turnover of HK$265 million.
Alibaba Pictures expects year-on-year losses in the previous fiscal year to Yingxinda Biotech's product revenue increase by more than 60% in the first quarter｜Selected Hong Kong Stock Announcements
① Alibaba Pictures expects to turn a year-on-year loss into a profit in the previous fiscal year. What is the revenue growth rate? ② Cinda Biotech's product revenue increased by more than 60% in the first quarter. What is the overall scale?
Cinda Biotech (01801.HK): Total product revenue in the first quarter exceeded 1.7 billion yuan, a strong year-on-year increase of more than 60%
On April 30, Gelonghui | Cinda Biotech (01801.HK) announced that in the first quarter of 2024, the company achieved total product revenue exceeding RMB 1.7 billion, a strong increase of over 60% over the previous year. The overall product portfolio continued to grow rapidly during the quarter, thanks to advantages such as broad indication potential, health insurance coverage and complete access channels. Dabershu (Cindilizumab Injection) continues to achieve strong sales performance and a stable market leading position. Other products have also grown significantly. In particular, new products have accelerated growth and continued to increase their contribution.
Innovent Biologics Names Samuel Zhang as Global Chief Business Officer
Innovent Biologics Names Samuel Zhang as Global Chief Business Officer
Cinda Biotech Announces Appointment of Dr. Zhang Suhua as Global Chief Commercial Officer
SAN FRANCISCO, SUZHOU, China, April 30, 2024/PRNewswire/ -- Cinda Biopharmaceuticals (HKEx stock code: 01801), a biopharmaceutical company dedicated to the development, production and sale of innovative drugs for major diseases such as oncology, autoimmunity, metabolism, cardiovascular, and ophthalmology, announced today the appointment of Dr. Samuel Zhang (Samuel Zhang) as Global Chief Commercial Officer (CBO). Dr. Zhang will be responsible for the strategic planning and business development of Cinda Biotech's global business and will report to Dr. Yu Dechao, the founder, chairman and CEO of the company. Dr. Zhang is in
信達生物：2023年報
Analysis
Price Target
No Data
